Introduction: Tobacco-related NSCLC is associated with reduced survival and greater genomic instability. Veliparib, a potent poly(adenosine diphosphate-ribose) polymerase inhibitor, augments platinum-induced DNA damage. A phase 2 trial of untreated advanced NSCLC showed a trend for improved outcomes (hazard ratio [HR] ¼ 0.80, 95% confidence interval: 0.54-1.18, p ¼ 0.27 for overall survival and HR ¼ 0.72, 95% CI: 0.45-1.15, p ¼ 0.17 for progression-free
. Sequencing data revealed that mutational burden was not associated with veliparib benefit. The rate of grade 3 or 4 adverse events was higher in recent smokers with veliparib treatment; all-grade and serious adverse events were similar in both treatment arms.
Conclusions:
Smoking history predicted for efficacy with a veliparib-chemotherapy combination; toxicity was acceptable regardless of smoking history. A prespecified analysis of recent smokers is planned for ongoing phase 3 studies of veliparib in NSCLC.
Introduction
Lung cancer is the leading cause of cancer-related death in the United States 1 and throughout the world. 2 Tobacco smoking remains the greatest risk factor for lung cancer. In most patients, lung cancer is diagnosed at an advanced stage, conferring poor prognosis. 3 Platinum-based combination doublets are the current standard of care for firstline chemotherapy for advanced NSCLC without treatable oncogenic alterations. [4] [5] [6] However, survival times and response rates remain low across various platinumcontaining regimens. 7 Therefore, novel therapies are needed to address the unmet medical need of patients with NSCLC.
Tobacco smoking is associated with a high level of genomic instability and specific patterns of mutations across multiple tumor types, including NSCLC of both the squamous and nonsquamous histologic subtypes. [8] [9] [10] In addition to being linked with these mutational signatures, smoking is also associated with greater mutational burden in NSCLC. 11 Veliparib is a potent, orally bioavailable inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2. 12 Veliparib has demonstrated increased cytotoxicity when combined with DNA-damaging agents (including platinum) [13] [14] [15] in preclinical studies and has been safely combined with full-dose carboplatin and paclitaxel in phase 1 and phase 2 clinical trials. [16] [17] [18] The M10-898 study (NCT01560104), a recently reported randomized phase 2 trial of previously untreated advanced NSCLC, showed a trend for improved overall survival (OS) and progression-free survival (PFS) in the overall population when veliparib was added to carboplatin and paclitaxel (hazard ratio [ 18 This exploratory analysis evaluates the impact of smoking history on clinical outcomes and mutational status of genes related to DNA damage and repair in patients treated with veliparib and carboplatin/paclitaxel in the M10-898 study.
Methods

Study Design and Patients
In this multicenter, randomized, double-blind, placebo-controlled phase 2 study, all eligible patients were randomly assigned to receive either veliparib or placebo in combination with carboplatin/paclitaxel with 2:1 randomization stratified by histologic subtype (squamous cell or nonsquamous cell) and by patientreported smoking history (recent smoker, former smoker, or never-smoker). 18 The recent smoker group was defined as patients who reported smoking within 12 months of study entry and had more than 100 smoking events (e.g., cigarettes) in their lifetime; former smokers were patients who had not smoked in the past 12 months and had more than 100 smoking events (e.g., cigarettes) in their lifetime; and the never-smoker group was defined as having 100 or fewer smoking events. Although the standard nomenclature current smoker (smoked within 12 months of study start, but not necessarily during treatment) is used for stratification, this term suggests that the patient was smoking while being treated. Because many patients stratified as current smokers were not smoking during treatment, we recommend using the term recent smoker to better describe this cohort of patients. Plasma samples were assessed for levels of cotinine at cycle 1 and cycle 3 to determine smoking status.
Patients with a confirmed diagnosis of NSCLC who had not received prior chemotherapy for advanced-or metastatic-stage disease (stage IIIB or IV) were included. Prior adjuvant chemotherapy for early-stage NSCLC was allowed if at least 12 months had elapsed. Additional key inclusion criteria were age older than 18 years, life expectancy longer than 12 weeks, presence of measurable disease, and performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale. Key exclusion criteria were brain metastases, receipt of external beam radiotherapy within 8 weeks, prior therapy with a PARP inhibitor, history of seizures, grade 2 or higher peripheral neuropathy, and severe uncontrolled comorbid conditions. Case report forms containing a detailed set of queries were completed for each patient screened/enrolled in the study (Supplementary Fig. 1 ). Smoking history was obtained at the time of study enrollment. All patients provided written informed consent approved by the institutional review board of the participating site. The study was performed according to the Good Clinical Practice guidelines and the Declaration of Helsinki.
Study Procedures and Treatment
Eligible patients were treated with veliparib or placebo at 120 mg orally twice daily on days 1 to 7 of each 3-week cycle. Carboplatin and paclitaxel were given on day 3 of each treatment cycle. Carboplatin was dosed to achieve an area under the concentration-time curve of 6 mg/mL/min according to the Calvert formula, and paclitaxel was given at a dose of 200 mg/m 2 . Treatments were continued to six cycles (no maintenance chemotherapy), unless discontinued for disease progression, clinical deterioration of the patient, pregnancy, withdrawal of informed consent, concomitant medical conditions limiting further therapy, or investigator's decision to discontinue therapy on the basis of the best interests of the patient.
Assessments
Tumor assessments were performed with computerized axial tomography scans of the involved areas at baseline and every 6 weeks during study treatments. Archived tumor tissue was collected from patients at baseline. Blood samples for veliparib PK assessment were collected before dosing and at 0.5, 1, 2, and 3 hours after veliparib or placebo dose on day 3 of cycle 1. Additional predose samples were collected on day 3 of cycles 2 to 4. Veliparib PK parameters were determined by using noncompartmental methods. Cotinine was measured by highperformance liquid chromatography in patient plasma samples as a chemical index of recent tobacco exposure, and levels higher than 10 ng/mL were considered high. 19 The primary objective was to assess whether the addition of veliparib to carboplatin and paclitaxel would improve PFS compared with placebo plus carboplatin and paclitaxel. Secondary objectives included assessment of OS, objective response rate (ORR), duration of overall response (DOR), safety and tolerability, and exploratory biomarker analyses. Responses were assessed by central independent review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria, version 4.0. For patients who discontinued therapy before progression of disease, imaging studies were done every 6 weeks until documentation of progression.
Analyses
The log-rank test, stratified by histologic subtype (squamous cell versus nonsquamous cell) was used to compare PFS determined by central imaging review at the time of 78 PFS events (the study's primary end point), and OS between treatment groups. An exploratory analysis of a Cox proportional hazard model adjusting imbalanced baseline factors (sex and ECOG PS) was performed for the end points PFS and OS. ORR and DOR were also analyzed. The distribution of DOR was estimated for each treatment group by using KaplanMeier methodology.
PFS and OS were evaluated in the smoking history subgroups (recent, former, and never). Sensitivity analyses of PFS and OS were performed on the basis of pack-years (calculated as patient-reported years of smoking times number of packs per day) in the pooled recent and former smokers group. PFS and OS were also analyzed on the basis of plasma cotinine level (in the total population). To determine the influence of continued tobacco use during study treatment, PFS and OS were assessed by cotinine level within the recent smoker group. PK parameters were evaluated on the basis of cotinine level, and safety outcomes were evaluated on the basis of smoking history.
The association of treatment and baseline characteristics with outcomes was assessed by using Cox proportional hazard models. A univariate model containing a baseline factor by treatment/interaction was performed first to identify the possible predictors. Multivariate modeling was then performed; it included all baseline factors identified from the univariate model: smoking history (current smokers, former smokers, and never-smokers), histologic subtype, age, ECOG PS, sex, and geographic region.
In exploratory biomarker analyses (Supplementary Methods), whole exome sequencing was performed on matched tumor and normal samples with an Illumina 2500 sequencer (Illumina, Hayward, CA) (2 Â 100 base pairs) using SureSelect Clinical Research Exome kits (Agilent, Cedar Creek, TX). Tumor DNA was obtained by macrodissecting the tumor area (>50% tumor content) from formalin-fixed, paraffin-embedded slides. Matched normal DNA was isolated from lymphocytes of peripheral blood. ArrayStudio (Omicsoft Corporation, Cary, NC) was used for sequence alignment, somatic calling, and quality control. High-quality somatic mutation calling was made on 38 paired samples.
Mutational signatures were deciphered by using the framework developed previously. 8 The 96-substitution classification (as determined by substitution class and sequence context) 20 and samples were classified per published signature categories. 21 To determine mutational burden, the total number of somatic mutations in the protein coding region and splicing sites was calculated for each patient. 11 
Results
Characteristics
A total of 158 patients from 37 centers in eight countries were randomized 2:1 to receive carboplatin/ paclitaxel with either veliparib, 120 mg orally twice daily, or placebo. Median age was 62 years, 68% of patients were male, and 48% had the squamous subtype. Smoking history was a prespecified stratification factor and was collected before randomization of each patient. At study entry, 60% of patients (n ¼ 95) were selfreported recent smokers (within 1 year), 27% (n ¼ 42) were former smokers, and 13% (n ¼ 21) had never smoked ( 100 smoking events). Patient demographics and baseline characteristics of the recent smoker group were generally similar to those of the total population and are shown in Table 1 .
Safety and Pharmacokinetics
Adverse events (AEs) by treatment arm are summarized in Supplementary Table 1 for the overall population and the recent smoker group. The most common AEs in the recent smoker group were similar to those in the overall population. In the recent smoker group, all-grade AEs were similar between treatment arms (93% for placebo with carboplatin/paclitaxel versus 95% for veliparib with carboplatin/paclitaxel), as were serious AEs (27% for both). The rate of grade 3 or 4 AEs was significantly higher with the veliparib combination than with carboplatin/paclitaxel alone in both the overall population and in the recent smokers subgroup (65% versus 50% [p ¼ 0.086] and 66% versus 40% [p ¼ 0.026], respectively). Disease progression was the most common reason for study discontinuation in the veliparib and placebo groups for recent smokers (64.1% and 58.1%), former smokers (60.7% and 71.4%), and never-smokers (61.5% and 100%).
The influence of smoking on veliparib PK was assessed by using cotinine as an indicator of concurrent smoking. Veliparib PK parameters did not significantly vary by cotinine level (Fig. 1) ; there were no clear veliparib in both the overall population and recent smoker group (see Supplementary Table 4) . Waterfall plots in Figure 3 show the best tumor size percentage change from baseline for each patient in each treatment, grouped by smoking history.
Sensitivity Analyses. The improvement in PFS and OS with veliparib seen in self-reported recent smokers was also observed in all patients with chemical evidence of smoking, as defined by a plasma cotinine level higher than 10 ng/mL (see Fig. 2) . A separate sensitivity analysis (based on current smokers and former smokers) was performed with smoker group defined according to packyears of smoking (more than the median of 39 pack-years history versus fewer than the median), which is a commonly used measure of smoking history. An improvement in PFS and OS with veliparib was also present in heavy smokers, defined as 39 or more pack-years of smoking among recent and former smokers (see Fig. 2 ). This benefit was not observed in the subgroup with a low cotinine level, which predominantly comprised the former smokers and never-smokers. Benefit was also not observed in recent smokers or former smokers who smoked fewer than 39 pack-years.
Impact of Smoking during Study Treatment.
To evaluate the impact of smoking during study treatment, self-reported recent smokers (within 12 months of study entry) were grouped by chemical evidence of smoking. Improved PFS and OS with veliparib was observed in selfidentified recent smokers, regardless of evidence of recent tobacco exposure (Supplementary Table 5 and Fig. 2 ).
Multivariate Analysis of Baseline Characteristics. The association of treatment and baseline characteristics (including smoking history) with outcomes was assessed using Cox proportional hazard models. In univariate analyses, several baseline factors predicted PFS and OS benefit of the veliparib-chemotherapy combination (p < 0.10 in at least one subgroup of a baseline factor). However, smoking history was the only factor with a significant interaction with study treatment (p ¼ 0.0009 and 0.001 for PFS and OS, respectively) (Supplementary Table 6, Supplementary  Table 7 , and Fig. 4) . A multivariate analysis that included all baseline characteristics identified self-reported smoking within 12 months of study entry as the single factor most predictive of veliparib benefit (p ¼ 0.04 for both PFS and OS in the recent smoker group).
Correlative Studies
In exploratory analyses to determine the association between smoking history and mutational patterns in this study, whole exome sequencing was performed on archival tissue samples. Of the 38 patients evaluable for somatic mutational signature scores, 8, 21 26 were determined to have tested positive for a smoking-related signature (signature 4 [score >0]), of whom 25 were recent or former smokers (n ¼ 15 and 10, respectively) and one was a never-smoker. Additionally, of all the 30 somatic mutational signatures calculated, 20 signature 4 score was identified to have the highest degree of association with smoking history category (p ¼ 0.036 by the Kruskal-Wallis test). This correlation was consistent with that observed in NSCLC samples from The Cancer Genome Atlas database (p ¼ 8 Â 10 -20 ). Increased mutational burden was observed among recent and former smokers, with a mean of 199 somatic "tier 1" mutations 22 in recent or former smokers versus 60 in never-smokers (p ¼ 0.004, two-sided t test). Three tumor tissues harboring DNA polymerase delta 1, catalytic subunit gene (POLD1) or DNA polymerase epsilon, catalytic subunit gene (POLE) mutations were excluded from the mutational burden analysis. Both enzymes are a high-fidelity polymerase; mutations in either gene can lead to deficiencies in faithful DNA replication and cause a hypermutator phenotype, skewing the mutagenic effect of cigarette smoking. Among the cohort of patients with available sequencing data, mutational burden was not associated with veliparib benefit (p ¼ 0.84, Cox proportional hazard model).
Discussion
The findings of this prespecified analysis of smokers demonstrate that recent smokers treated with veliparib derive significantly greater PFS and OS benefits, as well as higher ORR and DOR, compared with patients treated with only carboplatin/paclitaxel. Smokers had similar magnitudes of benefit irrespective of whether they had low or high levels of cotinine. Exploratory analysis of veliparib benefit according to pack-years of smoking showed similar results, although there is no validation set in which to formally examine this observation. These improvements in outcomes in the veliparibchemotherapy combination group versus in the chemotherapy-alone group concur with results reported for the overall population (squamous or nonsquamous), with greater benefit for the squamous histologic subgroup. 18 This study also showed that smoking history is a strong independent predictor for the efficacy of veliparib in combination with carboplatin/paclitaxel as a first-line therapy in advanced NSCLC.
AE rates were higher in the veliparib group than in those receiving placebo independent of the population analyzed (overall population and current smokers). Though partially apparent in the incidence of anemia, alopecia, and leukopenia, many other specific events reflected this difference. For all grades, the rates of neutropenia and arthralgia were similar across the overall population and current smokers but higher in veliparib-treated than placebo-treated patients. The observed AEs in recent smokers were manageable and generally consistent with toxicities of patients with lung cancer who receive treatment with veliparib.
The consistent veliparib benefit observed in the two cotinine cohorts suggests that the efficacy of veliparib in smokers is not dependent on tobacco exposure during study treatment. PK data did not significantly vary in the cohorts with high and low cotinine levels, indicating there were no changes in drug exposure. The observation that recent smokers, as opposed to former smokers or never-smokers, benefit from veliparib treatment is of interest and contrasts with what is seen in patients with lung cancer treated with chemotherapy or radiotherapy or with other targeted agents.
A number of trials have demonstrated that patients with solid tumors who are active smokers at diagnosis have poorer treatment outcomes than their nonsmoker counterparts. 23, 24 Patients with tobacco-related malignancies, such as lung cancer or head and neck cancer, who continue to smoke during anticancer treatment have been shown to have increased symptom burden, 25 with lower rates of response to chemotherapy, radiotherapy, or chemoradiotherapy, and they may exhibit poorer survival. [26] [27] [28] Targeted agents used in lung cancer, such as erlotinib, afatinib, ceritinib, and crizotinib, predominantly exhibit efficacy in patients who have never smoked and harbor oncogenic activating mutations of EGFR or anaplastic lymphoma receptor tyrosine kinase gene (ALK). There are very few reports of their use in patients who are currently smokers. However, a converse association has been observed with immunotherapies, as they tend to perform better in patients with a history of prior smoking. Currently, this effect is hypothesized to be based on a higher mutational burden in these patients. 8, 29 Rapidly proliferating cancers, such as lung cancer, tend to be genetically unstable and exhibit divergent genomic instability processes over time. This may lead to the appearance of various mutations that result in defective DNA repair, and may lead to more aggressive tumor behavior. 30 For smokers, the inhalation of tobacco smoke and its associated procarcinogens and carcinogens contribute to the process of mutagenesis and can accelerate and/or promote genetic instability, which contributes to worsened outcomes. 31 This is evidenced by the observation that a greater mutational burden is seen in smoking-related versus non-smoking-related lung cancers. 11 In the exploratory biomarker analyses of the limited sequencing data cohort in this study, smoking history was associated with the presence of mutational signature 4, a pattern consistent with smoking history in larger reference genomic data sets in NSCLC, as well as in other tumor types. 8 Signature 4 shows transcriptional strand bias for C>A change, which is likely the imprint of the bulky DNA adducts generated by polycyclic hydrocarbons found in tobacco smoke and their removal by transcription-coupled nucleotide excision repair. 32 This C>A transversion is characteristic of smoking-related genotoxicity and indicates an increased mutational burden in those who have smoked. PARP inhibitors have previously been used to successfully target DNA repair pathways in patients with breast cancer 1/2 gene (BRCA)-associated cancers (e.g., Tutt et al. 33 ), and they are believed to be a valid approach to prevent and/or treat genomic instability. 34 Consequently, the observed efficacy of veliparib in recent smokers may reflect the effect of this drug on DNA repair pathways and in reducing genomic instability. Analysis of limited sequencing data from this study did not show a strong association of mutational burden and veliparib benefit, suggesting that a different measure of genomic instability may be needed to identify a set of tumors susceptible to veliparib therapy.
The results presented herein are a post hoc subanalysis of the original trial. 18 Hence, the sample size is small and care must be taken when drawing conclusions. The whole exome data set is small, and this precludes conclusive comparison between treatment arms. However, it is noteworthy that the reported sequencing data are consistent with other large-scale lung cancer sequencing projects. Although the association between smoking and PARP inhibitor benefit is not clearly understood, data from additional trials may be used to further define the relationships among number of smoking events, timing of smoking start and smoking cessation, mutational burden, and response to therapy. Phase 3 trials with larger sample sizes are under way to further evaluate these observations and may better define the group of smokers most likely to benefit (squamous histologic subtype [M11-089, NCT02106546] or nonsquamous histologic subtype [M14-359, NCT02264990]). The primary end point in both studies is to assess the outcomes in recent smokers. Data from these trials will be used to make informed decisions about the use of veliparib in these patient populations.
